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Abstract 
 
A rapid sandwich enzyme linked immunoassay (ELIA) procedure was developed for the highly sensitive detection of 
human Lipocalin-2 (LCN2), also known as neutrophil gelatinase-associated lipocalin (NGAL). It reduced the total 
immunoassay duration by more than 3-fold and detected LCN2 in the pathophysiological range of 2.5-5120 pg/mL 
with an analytical sensitivity of 7 pg/mL, which is about 11-fold better than that of the commercially-available 
conventional enzyme linked immunosorbent assay (ELISA). The enhanced analytical performance of developed 
ELIA procedure is due to the leach-proof covalent crosslinking of anti-human LCN2 antibody to the 3- 
aminopropyltriethoxysilane (APTES)-functionalized microtiter plate (MTP) by 1-ethyl-3-[3- 
dimethylaminopropyl]carbodiimide hydrochloride. The multisubstrate-compatible ELIA procedure enables LCN2 
assay on different types of polymeric substrates (inert, hydrophilic and hydrophobic) using the modified MTP format. 
The developed ELIA procedure can be similarly employed to develop rapid and highly sensitive immunoassays for 
other disease biomarkers and analytes in clinical and industrial settings. 
 
© 2011 Published by Elsevier Ltd. Selection and/or peer-review under responsibility of the Institute of 
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1. Introduction 
 
LCN2/NGAL is a small 25 kDa secretory glycoprotein found in neutrophils and certain epithelia such 
as renal tubules [1]. LCN2 expression is dramatically increased in ischemic [2] or nephrotoxic injury [3]. 
It is an early and sensitive biomarker for acute renal injury [4,5] as its levels rise in urine and blood just 
within a few hours. Higher levels of LCN2 may lead to acute renal failure. It is also relevant in cases of 
cardiovascular surgery; coronary heart disease [6]; kidney transplants [7,8]; bacterial infections [9]; fatty 
liver  disease;  obesity  and  its  associated  pathologies;  several  types  of  cancers  such  as  breast  [10], 
pancreatic [11], ovarian [12] and oesophageal [13]; and, obesity-induced metabolic disorders [14] such as 
insulin resistance, type 2 diabetes mellitus and cardiovascular disorders. The prognosis of acute renal 
failure is usually done by creatinine or cystatin C measurements but they respond only after a few days of 
the renal function deterioration.   The down-regulation of LCN2 is also a diagnostic marker for many 
diseases such as glioblastoma [15], where LCN2 is down-regulated as a subsidiary mechanism of 
enhancing chemoresistance in glioblastoma cells. The LCN2 threshold is also down-regulated in ovarian 
cancer [12] and microglial cells [16]. Studies have also suggested that LCN2 is a predictive marker for 
excessive exposure to high electromagnetic fields that significantly decreases the body threshold of LCN2 
[17]. Therefore, LCN2 has an important prognostic and diagnostic value as a biomarker. The LCN2 
concentrations in urine and plasma of healthy persons are in the ranges of 0.7-9.6 ng/mL and 37–106 
ng/mL, respectively. It rises immediately after renal injury in urine and plasma, where its concentrations 
are in the range of 110-40,000 ng/mL and 25-3491 ng/mL, respectively. However, in case of acute renal 
failure, the NGAL concentrations in urine and plasma are above 350 ng/mL and above 400 ng/mL, 
respectively. 
Several sandwich ELISA kits have been made in the last few years, which can reliably determine the 
pathophysiological LCN2 levels in the biological samples. However, we have developed a rapid and 
highly-sensitive sandwich ELIA procedure based on the covalent binding of anti-human LCN2 antibodies 
on the APTES-functionalized surface (Fig. 1). It has 11-fold better sensitivity, 3-fold reduced overall 
assay duration, greater reproducibility and lesser variability than the conventional ELISA that is being 
used in several commercially existing kits. The commercially available human LCN2 sandwich ELISA 
kit, containing all the assay components, was employed. The developed and conventional procedures were 
evaluated under the same conditions at the same time using the same assay components. The multi- 
substrate compatibility of the developed ELIA enabled LCN2 assays on various types of commercially- 
relevant substrates using the modified microtiter plate (MTP) [18]. The developed ELIA procedure will be 
of great utility to develop rapid and highly sensitive immunoassays for other disease biomarkers and 
analytes. 
 
2. Materials and Methods 
 
2.1 Materials 
 
EDC, N-hydroxysuccinimide (NHS), N-hydroxysulfosuccinimide (sulfoNHS), phosphate buffered 
saline (PBS, 0.1M, pH 7.4), 2-(N-morpholino)ethanesulfonic acid (MES, pH 4.7), 3,3ʹ,5,5ʹ- 
tetramethylbenzidine (TMB) substrate kit and bovine-serum albumin (BSA) were purchased from Thermo 
Scientific. Potassium hydroxide (KOH), 3-APTES, Tween 20 and absolute ethanol were obtained from 
Sigma-Aldrich.  The  human  LCN2/NGAL  Duoset  kit,  with  all  sandwich  ELISA  components,  was 
procured from RnD Systems, USA. Anti-human LCN2 antibody was used as capture antibody, whereas 
biotinylated anti-human LCN2 detection antibody and streptavidin-conjugated horseradish 
peroxidasewere  employed  for  detection.  0.1M  PBS,  pH  7.4  with  1%  (v/v)  BSA  was  used  for 
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reconstituting all assay components, whereas ultrapure water (UPW) (18 MΩ, Direct Q, Millipore) was 
used for preparing buffers, KOH and 3-APTES. EDC, NHS and SNHS were reconstituted in 0.1M MES 
buffer, pH 4.7. 
Poly(methyl methacrylate) (PMMA), polystyrene (PS) and zeonexTM (Znx) slides were purchased 
from Microfluidic Chip Shop GmbH, Germany. Polycarbonate (PC) and cellulose acetate (CA) were 
received from VTT, Finland, whereas Zeonor (Znr) was procured from Zeon Chemicals, Germany. 
Pressure-sensitive adhesive (PSA) was obtained from Adhesive Research. Bottomless 96-well MTPs were 
purchased from Greiner Labortechnik, Germany. The assay temperature was maintained at 37°C using a 
thermostat from Labnet International Inc., USA. Absorbance was measured using Tecan Infinite M200 
Pro instrument procured from Tecan GmbH, Austria. 
 
 
Fig. 1. Schematic of covalent crosslinking of antibody in the developed human Lipocalin-2 sandwich ELIA. 
 
2.2 Methods 
 
2.2.1 Preparation of anti-human LCN2 antibody-bound MTP 
 
Each well of the 96-well MTP was treated with 100 μ L of absolute ethanol for 5 min at 37°C and 
washed five times with 300 μ L of UPW.  Subsequently, each well was treated with 100 μ L of 1.0% (w/v) 
KOH at 37°C for 10 min followed by five washings with 300 μ L of UPW. The KOH-treated wells were 
then functionalized with amino groups by incubating with 100 μ L of 2% (v/v) APTES per well at room 
temperature for 1 h inside the fume cabinet. The amine-functionalized plate was subsequently washed five 
times with 300 μ L of DIW in order to remove excess unbound 3-APTES from the surface. Thereafter, 
anti-human LCN2 (990 μ L of 2 μ g/mL) was incubated with 10 μ L of EDC (4 mg/mL) for 15 min at 37°C. 
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The resulting EDC-activated anti-human LCN2 antibody solution was added to each of the functionalized 
wells (100 μ L) and incubated for 1 h at 37°C.  The anti-human LCN2 antibody-bound wells were then 
washed six times with 400 μ L of PBST (0.05% Tween 20 in PBS, pH 7.2). 
 
2.2.2 Sandwich ELIA procedure 
 
The anti-human LCN2 antibody-bound MTP wells were blocked with 1% (v/v) BSA, diluted in 0.1M 
PBS, pH 7.4, for 30 min at 37°C and subsequently washed six times with 400 μ L of PBST. 100 μ L of 
each of the varying concentrations of human LCN2 (2.5-5120 pg/mL), prepared in 0.1M PBS with 1% 
BSA, pH 7.4, were incubated in the anti-human LCN2 antibody-coated MTPs for 1 h at 37°C followed by 
washing with 400 μ L of PBST six times. 100 μ L of biotinylated anti-human LCN2 detection antibody 
(100 ng/mL) was then added and incubated for 1 h at 37°C followed by six washes with 400 μ L of PBST. 
100 μ L of SA-HRP, diluted 1:200, was then added to each well and incubated for 20 min at 37°C 
followed  by  six  washes  with  400  μ L  of  PBST.  The  TMB  substrate  was  then  added  (as  per  the 
manufacturer’s guidelines) and the enzyme-substrate reaction was stopped after 20 min by adding 50 μ L 
of 2N H2SO4. The absorbance was measured at 450 nm with reference at 540 nm (to eliminate the optical 
imperfections at well-to-well level).  All the experiments were done in triplicate with zero ng/mL human 
LCN2 (in 0.1M PBS, pH 7.4 with 1% BSA) as control, whose absorbance was subtracted from all the 
assay values. 
The preparation of modified MTPs, used to perform sandwich human LCN2 ELIA on different 
polymeric substrates, has been described elsewhere [18]. The conventional sandwich ELISA procedure 
was followed as per the manufacturer’s guidelines provided in the product information sheet without any 
modification. 
 
2.2.3 Assay performance analysis 
 
All datasets obtained from the developed ELIA and conventional ELISA procedures were subjected to 
four-parameter logistic function-based standard curve analysis in the Sigma Plot software, version 11.2. 
The EC50, Rsqr, hillslope values were determined from the report generated by the software. The 
analytical sensitivity was calculated by [mean absorbance of blank + 3(standard deviation of the blank)]. 
The variability was reported as percentage coefficient of variation (%CV). The intra-assay and inter-assay 
variability were calculated from six assay repeats (in triplicate) on a single day and on six different days, 
respectively. All the assays were carried out in triplicate. 
 
3.    Results and Discussion 
 
The developed sandwich ELIA detected human LCN2 in the range of 2.5-5120 pg/mL (r2=0.99) with an 
analytical sensitivity of 7 pg/mL [Fig. 2(a)]. The intra-assay and inter-assay variability were 1.1-11.8 and 
1.9-14.5, respectively, while the percentage recovery for the various concentrations of human LCN2 was 
between 85 and 110. The maximal half-effective concentration (EC50) obtained from the assay curve was 
very  low  i.e.  624  pg/mL,  which  demonstrated  the  high  sensitivity  of  developed  ELIA.  The  high 
sensitivity was mainly due to the covalent crosslinking of capture antibody that led to the leach-proof 
binding of antibodies to the substrate with high immobilization density. The developed ELIA procedure is 
an improvement of our previous immunoassay procedure [19,20], which requires additional steps of 
oxygen plasma treatment and silanization at 80 °C under vacuum. The developed ELIA have no such 
limitations and can be employed in any bioanalytical lab. The optimization of antibody-crosslinking on 
APTES-functionalized MTP further revealed that EDC alone crosslinks antibodies more efficiently than 
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EDC in  combination with  sulfoNHS or  NHS [Fig.  2  (b)].  2%  APTES was the  optimized APTES 
concentration [Fig. 2 (c)], while 1 h was the optimum silanization time [Fig. 2 (d)]. 
 
 
Fig. 2. (a) Comparison of the developed sandwich ELIA for human LCN2 with the conventional ELISA. (b) Comparison of various 
EDC-based antibody crosslinking strategies for the developed human LCN2 sandwich ELIA. (c) Optimization of APTES 
concentration used for silanization. (d) Optimization of duration of silanization. (e) Developed human LCN2 sandwich ELIA on 
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different types of commercially-relevant substrates i.e. hydrophobic (PS, PC, PMMA), hydrophilic (CA), and inert (cyclo-olefin 
polymers; with trade names of Zeonex and Zeonor). All the experiments were done in triplicate. The error bars represent standard 
deviations. 
 
The performance of the developed ELIA was compared to that of conventional ELISA (Table 1) by 
performing both the immunoassays simulataneously on the same day under the same conditions. The 
dynamic range of conventional human LCN2 ELISA was 40-5120 pg/mL (r2=0.99), while its analytical 
sensitivity was 80 pg/mL that was about 11-fold less sensitive than that of developed ELIA. Moreover, 
the overall immunoassay duration of developed ELIA (~6 h) was greater than 3-fold lesser than that of 
conventional ELISA (~20 h). Additionally, the developed ELIA had less variability than that of 
conventional ELISA. 
In industrial settings, the passively adsorbed antibody-coated MTPs are kept refrigerated for about 2 
weeks so that they can be used immediately to detect specific analytes whenever required. However, the 
developed ELIA has completely eliminated the storage of antibody-coated MTPs as the overall 
immunoassay, including the antibody immobilization, takes only 6 h. It enhances the quality of 
immunoassays by eliminating the storage-based effects. The developed human LCN2 ELIA was 
performed on various types of polymeric substrates i.e. hydrophobic (PS, PC, PMMA), hydrophilic (CA) 
and inert (cyclo-olefin polymers with trade names of Zeonex and Zeonor) using the modified MTP format 
[18] [Fig. 2 (e)]. However, as these substrates have varying thicknesses, the human LCN2 assays 
performed on them cannot be compared because the absorbance is dependent on the optical path length. 
The developed human LCN2 ELIA is the most sensitive assay reported so far based on its comparison 
with various commercially-available ELISA kits (Table 2). However, the commercial kits may have 
different assay components such as monoclonal or polyclonal antibody types, which may be responsible 
for their lower sensitivity as the nature of the antibody determines the antigen capture efficiency and thus 
the sensitivity and specificity of an immunoassay. The developed ELIA procedure will be of tremendous 
utility to develop rapid and highly sensitive immunoassays for other disease biomarkers and industrial 
analytes. 
 
4.    Conclusion 
 
A rapid sandwich ELIA procedure, based on the covalent crosslinking of anti-human LCN2 antibodies 
to APTES-functionalized microtiter plate, was developed for the highly sensitive detection of human 
LCN2. It is the most sensitive assay format reported so far for human LCN2. It was about 11-fold more 
sensitive, 3-fold more rapid and more reproducible than the conventional ELISA procedure, which is 
being used in most commercially-available diagnostic kits. It has completely eliminated the requirement 
of storing antibody-bound MTPs in industrial settings. It can be further employed to perform human 
LCN2 assay on various types of commercially-relevant polymeric substrates using the modified MTP 
format. The developed ELIA has much better analytical performance than the conventional ELISA and 
can be effectively used for immunoassays in clinical and industrial settings. 
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Table 1.  Analytical comparison of the developed sandwich ELIA for human LCN2/NGAL with the conventional ELISA. 
Developed ELIA Conventional ELISA 
 
Detection Range (pg/mL) 2.5-5120 40-5120 
 
LOD (pg/mL) 3 44 
Analytical Sensitivity (pg/mL) 7 80 
EC50 (pg/mL) 624 821 
% CV 
Intra-day (n=6) 
Inter-day (n=6) 
1.1-11.8 
1.9-14.5 
1.6-17.2 
2.4-18.1 
Assay duration (hours) ~6 ~20 
Assays on various substrates Yes No 
 
 
 
Table 2. A comparative analysis of the developed human LCN2/NGAL sandwich ELIA with various commercially-available 
sandwich ELISA kits. 
Manufacturer Antibody immobilization 
technique 
LOD* Refer to 
 
Covalent assay Chemical crosslinking 2.5 pg/mL Reported in this manuscript 
 
Passive assay Passive adsorption 40 pg/mL Reported in this manuscript 
 
R&D Systems, Inc Passive adsorption 78 pg/mL www.rndsystems.com 
 
Boster Biological Technology 
Co., Ltd. 
Antibody and Immunoassay 
Services 
Passive adsorption 10 pg/mL www.immunoleader.com 
 
Passive adsorption 0.4 ng/mL www.antibody.hku.hk 
Meso Scale Diagnostics Passive adsorption  www.mesoscale.com 
BioPorto Diagnostics Passive adsorption 0.2 ng/mL www.bioporto.com 
CycLex Co., Ltd Passive adsorption 26.7 pg/mL www.cyclex.co.jp 
BioVendor Passive adsorption 20 pg/mL www.biovendor.com 
Argutus Medical Passive adsorption 0.4 ng/mL www.argutusmed.com 
 
 
*the lowest concentration detected by the assay. 
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